Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kiniksa Pharmaceuticals reports robust Q2 growth and strategic initiatives

Kiniksa Pharmaceuticals delivered a strong Q2 performance with significant revenue growth driven by ARCALYST sales and strategic initiatives. The company's focus on disease awareness and patient base expansion bodes well for future growth.
While challenges such as managing expenses and addressing operational complexities persist, Kiniksa's solid financial position and market opportunities position it favorably for sustained growth and value creation.
Overall, Kiniksa Pharmaceuticals' Q2 earnings call highlights a mix of strong performance, strategic strengths, operational challenges, and growth opportunities, signaling a dynamic and evolving landscape for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

– Rilonacept pivotal Phase 3 trial in recurrent pericarditis met statistical significance for primary and all major secondary efficacy endpoints; sBLA submission expected this year –

Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity

HAMILTON, Bermuda, July  21, 2020  (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 5,952,381 Class A common shares at a public offering price of $21.00 per share, before underwriting discounts and commissions. The gross proceeds to Kiniksa from this offering, together with the proceeds of the sale of 1,428,572 Class A1 common shares in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, before fees and estimated expenses, are expected to be approximately $155.0 million. In addition, Kiniksa has granted the underwriters a 30-day option to purchase up to 892,857 additional Class A common shares at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on July 24, 2020, subject to customary closing conditions. All of the Class A common shares are being offered by Kiniksa.

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering

HAMILTON, Bermuda, July  20, 2020  (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of $100.0 million of Class A common shares. In addition, Kiniksa expects to grant the underwriters a 30-day option to purchase up to $15.0 million of additional Class A common shares. All of the Class A common shares are being offered by Kiniksa.

Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering

HAMILTON, Bermuda, July  16, 2020  (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals, Ltd.  (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for rilonacept for the treatment of pericarditis, which includes recurrent pericarditis. Rilonacept is a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling.

Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis

Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) shares were trading higher Monday after the company's Phase 3 trial of Rilonacept showed statistically significant results.

Why Kiniksa's Stock Is Trading Higher Today

eXp World Holdings Inc

iClick Interactive Asia Group

Lakeland Industries

Meridian Bioscience

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

5 Stocks With Recent Price Strength Amid Spike in Coronavirus

HAMILTON, Bermuda, June  29, 2020  (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, reported positive data from RHAPSODY, a pivotal Phase 3 trial of rilonacept, a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling, in recurrent pericarditis. RHAPSODY met its prespecified primary and all major secondary efficacy endpoints, showing that rilonacept improved clinically meaningful outcomes associated with the unmet medical need in recurrent pericarditis, a painful and debilitating autoinflammatory disease. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to rilonacept for the treatment of recurrent pericarditis in 2019, and Kiniksa expects to submit a Supplemental Biologics License Application (sBLA) later this year.

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)

Calix

Sunopta

5 Stocks With Recent Price Strength on Upbeat Economic Data

Kiniksa Positive COVID-19 Data And Other News: The Good, Bad And Ugly Of Biopharma

HAMILTON, Bermuda, June  08, 2020  (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced the presentation of 28-day clinical outcomes data from the open-label treatment protocol with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in severe coronavirus 2019 (COVID-19) pneumonia and hyperinflammation at the European E-Congress of Rheumatology (EULAR) 2020. The company also announced an active investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for its global placebo-controlled Phase 2/3 clinical trial of mavrilimumab in severe COVID-19 pneumonia and hyperinflammation. Additionally, an investigator-initiated placebo-controlled study in the U.S. is enrolling patients.

Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial

HAMILTON, Bermuda, May  29, 2020  (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced an upcoming presentation, entitled Mavrilimumab Improves Outcomes in Severe COVID-19 Pneumonia and Systemic Hyper-Inflammation, showing data from the open-label treatment protocol with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in patients with severe coronavirus 2019 (COVID-19) pneumonia and hyperinflammation will be delivered at the European E-Congress of Rheumatology (EULAR) 2020. Additionally, preclinical data analyzing the role of the granulocyte macrophage colony stimulating factor (GM-CSF) pathway in giant cell arteritis (GCA) pathophysiology will be included in a poster presentation.

Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020

Kiniksa Pharmaceuticals (KNSA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Kiniksa Pharmaceuticals (KNSA) Stock Stands Out in a Strong Industry

HAMILTON, Bermuda, May  18, 2020  (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the closing of its public offering of 2,760,000 of its Class A common shares at a public offering price of $18.25 per share, which includes the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds to Kiniksa from this offering and its previously announced concurrent private placement were approximately $80 million, before deducting fees and offering expenses payable by Kiniksa.

Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

HAMILTON, Bermuda, May  13, 2020  (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 2,400,000 of its Class A common shares at a public offering price of $18.25 per share, before underwriting discounts and commissions. The gross proceeds to Kiniksa from this offering, together with the proceeds from the sale of 1,600,000 Class A1 common shares at the public offering price in a concurrent private placement, before fees and estimated expenses, are expected to be $73,000,000. In addition, Kiniksa has granted the underwriters a 30-day option to purchase up to 360,000 additional Class A common shares at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on May 18, 2020, subject to customary closing conditions. All of the Class A common shares are being offered by Kiniksa.

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering

– Mavrilimumab treatment protocol in patients with severe COVID-19 pneumonia and hyperinflammation showed improved clinical outcomes compared to matched contemporaneous controls, including earlier weaning from supplemental oxygen, shorter hospitalizations, and no deaths –

Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus

As of late, it has definitely been a great time to be an investor Kiniksa Pharmaceuticals

Will Kiniksa Pharmaceuticals Continue to Surge Higher?

- Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8 -   - Statistically significant secondary efficacy endpoint of improvement in prurigo nodularis-investigator’s global assessment (PN-IGA) 0/1 at Week 8 -

Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint

Kiniksa announced an unexpected move into the COVID-19 furore.

Kiniksa's Unexpected Play

Is  (KNSA) Outperforming Other Medical Stocks This Year?

Has Kiniksa Pharmaceuticals (KNSA) Outpaced Other Medical Stocks This Year?

AvroBio Inc

Fate Therapeutics

Mersana Therapeutics

Novocure

Orchard Therapeutics plc - ADR

Synlogic

Tcr2 Therapeutics

The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.

What Wedbush Is Watching in Biotechs Amid Coronavirus Crisis

  - All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation; follow-on controlled study in Italy planned -   - Consortium of U.S. academic sites planning to commence investigator-initiated studies in parallel -  - Evaluating a Phase 2/3 clinical development program pending regulatory feedback and data from treatment experiences -

Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation

- Phase 2 study data show the potential for rilonacept treatment to eliminate or reduce the risk of corticosteroid-associated morbidity in recurrent pericarditis -   - Enrollment complete for the pivotal Phase 3 trial of rilonacept in recurrent pericarditis (RHAPSODY); data expected in 2H 2020 -

Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session

Adaptimmune Therapeutics

Applied Therapeutics Inc

These three clinical-stage biotechs could all double in value before year's end.

3 Top Biotech Stocks to Buy in February

Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta

Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma

HAMILTON, Bermuda, Dec.  10, 2019  (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals, Ltd.  (Nasdaq: KNSA) announced today that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco, California. The presentation will be followed by a question and answer session that will begin at 2:30 p.m. Pacific Time / 5:30 p.m. Eastern Time.

News for Kiniksa Pharmaceuticals Ltd Stock (KNSA)